BioCryst Pharmaceuticals, Inc. (BCRX)
8.78
+0.15
(+1.74%)
USD |
NASDAQ |
Mar 03, 13:44
BioCryst Pharmaceuticals Cash from Investing (Quarterly) : -83.49M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 0.198M |
| KalVista Pharmaceuticals, Inc. | -- |
| Lantheus Holdings, Inc. | -11.51M |
| Plus Therapeutics, Inc. | 1.297M |
| BioStem Technologies, Inc. | -1.168M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 276.04M |
| Cash from Financing (Quarterly) | -202.04M |
| Free Cash Flow | 327.41M |
| Free Cash Flow Per Share (Quarterly) | 1.255 |
| Free Cash Flow to Equity (Quarterly) | 481.01M |
| Free Cash Flow to Firm (Quarterly) | 289.25M |
| Free Cash Flow Yield | 17.06% |